Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary ; volume:102 ; number:9 ; day:10 ; month:7 ; year:2023 ; pages:2555-2563 ; date:9.2023
Annals of hematology ; 102, Heft 9 (10.7.2023), 2555-2563, 9.2023
- Creator
-
Husi, Kata
Szabó, Roxána
Pinczés, László Imre
Földeák, Dóra
Dudley, Réka
Szomor, Árpád
Koller, Beáta
Gopcsa, László
Illés, Árpád
Miltényi, Zsófia
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-023-05354-8
- URN
-
urn:nbn:de:101:1-2023110608371323874966
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Husi, Kata
- Szabó, Roxána
- Pinczés, László Imre
- Földeák, Dóra
- Dudley, Réka
- Szomor, Árpád
- Koller, Beáta
- Gopcsa, László
- Illés, Árpád
- Miltényi, Zsófia
- SpringerLink (Online service)
Other Objects (12)
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Complete Remission of Relapsed Hodgkin’s Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Brentuximab Vedotin beim Hodgkin Lymphom und systemischen ALCL : CD30-Positive Lymphone
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Complete Remission of Relapsed Hodgkin’s Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Brentuximab Vedotin beim Hodgkin Lymphom und systemischen ALCL : CD30-Positive Lymphone
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Complete Remission of Relapsed Hodgkin’s Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Brentuximab Vedotin beim Hodgkin Lymphom und systemischen ALCL : CD30-Positive Lymphone